Concurrent 4MP treatment started from the time of tumor cell implantation (day zero) prevented EtOH from stimulating tumor growth, implicating ADH-mediated EtOH oxidation in the acceleration of ESCC tumor growth (Figure 10A). The gene discussed is AVP; the disease is neoplasm.